RUNX2 inhibitor CADD522 improves bone microarchitecture and lipid metabolism in post-menopausal bone loss Authors: Adel Ersek, Myoung Sook Kim, Caterina Suelzu, Isabelle Piec, Aerielle Matsangos, Elmar Nurmemmedov, Emma C. Bull, Tabitha Bartlett, Rachel Dunn, James R. Dick, Rena Lapidus, Danielle M. Copeman, Jonathan C. Y. Tang, Paul G. Crichton, Matthew G. Pontifex, William D. Fraser, Nicole J. Horwood, Antonino Passaniti, Darrell Green Published: 2026 ABSTRACT Osteoporosis is a leading cause of age-related morbidity, yet existing antiresorptive and anabolic therapies remain limited by safety concerns, contraindications and poor long-term adherence. CADD522 is a small molecule inhibitor of the RUNX2 transcription factor currently under development for cancer therapy. Here, we investigated whether RUNX2 inhibition could protect against post-menopausal bone loss. In an ovariectomy-induced mouse model, CADD522 (25 mg/kg, three times weekly for eight weeks) enhanced bone formation, preserved trabecular microarchitecture and reduced marrow and peripheral adiposity. Cross-species pharmacokinetic and toxicological studies demonstrated oral bioavailability, favourable short-term tolerability and target engagement despite rapid systemic clearance, while cellular thermal shift assays confirmed direct engagement of RUNX2. Together, these findings identify RUNX2 inhibition as a therapeutic strategy that simultaneously improves skeletal integrity and metabolic homeostasis, supporting further development of CADD522 for osteoporosis and other RUNX2-driven diseases. Introduction Osteoporosis is a metabolic bone disorder characterised by low bone mass, structural deterioration and increased fracture risk1. Osteoporosis affects one in three women and one in five men aged over 50 worldwide2 with ~20% one-year mortality following hip fracture and five-year survival rates comparable to thyroid and breast cancer3. Osteoporosis economic and healthcare burden is substantial, costing more than $20 billion annually in the US4. Osteoporotic fractures are the leading cause of hospitalisation in women aged >45 years in the UK5. Current therapies are limited. Antiresorptives such as bisphosphonates and denosumab reduce fracture risk2,6,7 but long-term use carries risks of atypical femoral fractures and osteonecrosis of the jaw8. Anabolic agents, including parathyroid hormone (PTH) derivatives and analogues, namely teriparatide and abaloparatide, are effective9 but require daily injection. Romosozumab offers monthly dosing but has cardiovascular safety concerns10. Hormone replacement therapy also reduces fracture risk11,12 but its association with breast, ovarian and uterine cancer risk limits patient uptake13. Thus, new treatments with few side effects and broader applicability remain a clinical priority. We recently evaluated the small molecule RUNX2 antagonist CADD522 in several preclinical cancer models14–17. RUNX2 is critical for in utero skeletogenesis18 and cancer metastasis19–22. Unexpectedly, CADD522 reduced cancer-induced bone disease, suggesting potential utility in osteoporosis14. We therefore tested CADD522 in a post-menopausal bone loss model, confirming significant therapeutic benefit. Supporting in vivo pharmacokinetic (PK), toxicology and in vitro drug property studies demonstrated tolerability and RUNX2 engagement, providing a foundation for future human absorption, distribution, metabolism, and excretion (ADME) optimisation. Results CADD522 improves bone microarchitecture in wild-type control and ovariectomised (OVX) mice Microcomputed tomography (µ-CT) analysis of tibias showed that the CADD522 regimen (Fig. 1a) increased bone volume in wild-type and OVX mice compared to empty vehicle controls (Fig. 1b, c). Bone surface density was unchanged in control mice but increased in OVX-CADD522 (Fig. 1d). Trabecular number was preserved in OVX-CADD522, comparable to control mice (Fig. 1e), while trabecular thickness was unaffected (Fig. 1f). Circulating procollagen type 1 N-propeptide (P1NP), a collagen formation biomarker, was elevated in OVX-CADD522 (Fig. 1g). C-terminal telopeptide of type 1 collagen (βCTX), a bone resorption marker, remained unchanged (Fig. 1h).Fig. 1CADD522 bone effects in 16 sham and 16 OVX C57BL/6 J female mice.Both experimental models received either vehicle (n = 8) or CADD522 (25 mg/kg three times weekly for 8 weeks; n = 8). a Schematic showing the CADD522 treatment schedule. b Microcomputed tomography (µ-CT) reconstructed images of tibiae. White arrows indicate enhanced bone volume/thickness. c Bone volume. d Bone surface density. e Trabecular number. f Trabecular thickness. g PINP plasma levels. h βCTX plasma levels. i Representative TRAP staining of the tibial bone marrow below the growth plate in control and OVX mice. Scale bars = 100 µM. CADD522 bone effects in 16 sham and 16 OVX C57BL/6 J female mice. Both experimental models received either vehicle (n = 8) or CADD522 (25 mg/kg three times weekly for 8 weeks; n = 8). a Schematic showing the CADD522 treatment schedule. b Microcomputed tomography (µ-CT) reconstructed images of tibiae. White arrows indicate enhanced bone volume/thickness. c Bone volume. d Bone surface density. e Trabecular number. f Trabecular thickness. g PINP plasma levels. h βCTX plasma levels. i Representative TRAP staining of the tibial bone marrow below the growth plate in control and OVX mice. Scale bars = 100 µM. Tartrate-resistant acid phosphatase (TRAP) staining was used to assess osteoclast number and distribution along trabecular bone surfaces. Control-vehicle mice exhibited a moderate number of TRAP-positive osteoclasts lining trabeculae in a discontinuous pattern (Fig. 1i). Control-CADD522 mice had reduced osteoclast number with sparse and localised TRAP-positive cells (Fig. 1i). In OVX-vehicle, TRAP-positive cells were rare, with minimal osteoclast attachment and increased marrow adiposity (Fig. 1i). In contrast, OVX-CADD522 showed a marked increase in TRAP-positive multinucleated osteoclasts distributed more continuously along trabecular surfaces (Fig. 1i). CADD522 reduces adipose tissue and improves lipid metabolism in OVX mice CADD522 reduced body weight in OVX but not control mice (Fig. 2a) independent of appetite (Supplementary Data 1). Bilateral inguinal fat pad weight was lower in OVX-CADD522 (Fig. 2b, c). Gross pathology revealed reduced white adipose tissue without obvious brown adipose tissue development (Fig. 2d). Histological analyses of the tibias showed reduced adipocyte deposits in the bone marrow of OVX-CADD522 (Fig. 2e). Consistently, CADD522 ligand interaction did not activate Uncoupling protein 1 (UCP1) from brown fat (Supplementary Fig. S1a, b). To investigate CADD522 effects on lipid metabolism, we profiled total and phospholipid-associated fatty acids in the lipid-rich brains of three mice from each experimental group (Fig. 2f, g). CADD522 induced widespread remodelling of the fatty acid landscape, with the most pronounced effects observed in the phospholipid fraction. Notably, treatment shifted phospholipid profiles towards those observed in non-OVX control animals, suggesting a partial restoration of menopause-associated lipid alterations (Fig. 2f). In the phospholipid fraction, the most pronounced CADD522 effects were in the long-chain saturated fatty acids (Fig. 2g). Treatment significantly reduced the abundance of arachidic acid, docosanoic acid and lignoceric acid in OVX mice, reversing the accumulation observed in vehicle-treated animals (Fig. 2f, g). Similarly, CADD522 reshaped the monounsaturated fatty acid profile, increasing palmitoleic acid and vaccenic acid levels while normalising elevated erucic acid and nervonic acid concentrations towards those observed in control animals (Fig. 2g).Fig. 2CADD522 adiposity effects in the same 16 sham and 16 OVX C57BL/6 J female mice.Both experimental models received either vehicle (n = 8) or CADD522 (25 mg/kg three times weekly for 8 weeks; n = 8). a Body weight. b Inguinal fat weight. c % inguinal fat/total body weight. d Representative suprascapula white adipose tissue gross pathology (white brackets). e Representative H&E staining of the tibial bone marrow below the growth plate. Scale bar=100 µM. f Global lipidomic analysis in n = 3 brains from all experimental groups. Left panel = % total fatty acid fraction. Right panel = % phospholipid fraction. g statistical significance in saturated fatty acids, monounsaturated fatty acids, and n-3 polyunsaturated fatty acids. CADD522 adiposity effects in the same 16 sham and 16 OVX C57BL/6 J female mice. Both experimental models received either vehicle (n = 8) or CADD522 (25 mg/kg three times weekly for 8 weeks; n = 8). a Body weight. b Inguinal fat weight. c % inguinal fat/total body weight. d Representative suprascapula white adipose tissue gross pathology (white brackets). e Representative H&E staining of the tibial bone marrow below the growth plate. Scale bar=100 µM. f Global lipidomic analysis in n = 3 brains from all experimental groups. Left panel = % total fatty acid fraction. Right panel = % phospholipid fraction. g statistical significance in saturated fatty acids, monounsaturated fatty acids, and n-3 polyunsaturated fatty acids. In contrast, CADD522 produced relatively modest effects on n-3 polyunsaturated fatty acids (Fig. 2f, g). Neither docosahexaenoic acid (DHA) nor total n-3 PUFA abundance was significantly altered by treatment, indicating that the metabolic effects of CADD522 were preferentially directed towards saturated and monounsaturated lipid pathways (Fig. 2g). CADD522 pharmacokinetics (PK), tolerability and comparative hepatic metabolism Pharmacokinetic and tolerability properties were assessed in mice, rats and dogs following intraperitoneal (IP), intravenous (IV) and oral (PO) administration (Fig. 3a). In CD-1 mice, high-dose oral CADD522 (40 mg/kg, single dose) reached peak plasma concentration (Cmax 60 mg/mL, ~184 µM) in 15 min and had a half-life of ~1 h (Fig. 3b). Eight-day, high-dose oral administration (40 mg/kg, BID) showed minimal toxicity with mild leukopenia (Fig. 3c) and mild increases in liver alkaline phosphatase (ALP) and cholesterol (Fig. 3d). In rats, IV dosing resulted in low exposure (mean AUC(0-inf) 0.376 h*µmol/L) and rapid systemic elimination with a short half-life (t½ 1.01 h; Fig. 4a, b; Table 1), whereas oral dosing increased exposure (AUC(0-inf) 0.988 h*µmol/L) and prolonged the terminal phase (t½ 3.95 h), with low inter-animal variability (Fig. 4c-f; Table 1). In dogs, IV administration yielded similarly low exposure (AUC(0-inf) 0.188 h*µmol/L) and more rapid clearance (t½ 20 min; Fig. 4g, h; Table 2), while oral dosing increased exposure (AUC(0-inf) 0.639 h*µmol/L), extended the half-life (t½ 39 min; Fig. 4i-l; Table 2) and resulted in moderate bioavailability (F = 67.5%; Table 2).Fig. 3Pharmacokinetics and tolerability in CD-1 (n = 6) and Nude (n = 5) mice.a Schematic showing CADD522 tolerability schedules and animals. b Plasma levels following single 40 mg/kg IP, IV or PO dosing (CD-1 mice). c Blood cell profiles after 8 days of twice-daily 40 mg/kg PO dosing (nude mice). d Organ toxicity markers (ALT, AST, ALP, ALB, Prot, Calc, CreatK, Uric, Trig, Chol, Gluc). Significant differences shown (p-values). WBC white blood cells/leukocytes, RBC red blood cells, NUT neutrophils, Mono monocytes, Baso basophils, Luc large unstained cells, which correlate with markers of immune activation and helper T cell (CD4) counts, ALT alanine transaminase, AST aspartate transaminase, ALP alkaline phosphatase, ALB albumin, Prot total protein, Calc calcium, CreatK creatinine kinase, Uric uric acid; Trig, triglycerides; Chol, cholesterol, Gluco glucose. Standard units on the x-axis are specific for each enzyme/metabolite.Fig. 4Pharmacokinetics after single dose in rats (n = 6) and dogs (n = 2).a–f Plasma concentrations in Sprague Dawley rats (IV 5 mg/kg, PO 25 mg/kg). g–l Plasma concentrations in Beagle dogs (IV 5 mg/kg, PO 25 mg/kg). Linear and log plots shown for individual and mean values. m in vitro hepatic clearance of 10 µM [14C]-testosterone and n 1 µM CADD522 in mice, rats, dogs, minipigs and humans. Experiments were performed in duplicate.Table 1Pharmacokinetic parameters of CADD522 following IV (5 mg/kg) and PO (25 mg/kg) administration to 6 male Sprague Dawley ratsRouteDose level (mg/kg)Animal numberC0(nmol/L)Cmax(nmol/L)Tmax (h)AUC(0-t)(umol/L)AUC(0-inf) (umol/L)T1/2 (h)Vz(L/kg)CL(mL/min/kg)F (%)IV5001 M5514100.08300.261NRNRNRNRNA002 M5253680.08300.2190.2600.88074.7981NA003 M6024690.08300.4550.4911.1451.2519NAN3.003.003.002.002.002.002.002.00NAMean5594150.08300.3120.3761.0170.0750NASD39.450.7NA126NANANANANACV%7.0412.2NA40.5NANANANANAPO25004 MNA38900.2501.341.454.58350a882aNA005 MNA2221.000.5010.5263.32699a2430aNA006 MNA1350.250NRNRNRNRNRNANNA3.003.002.002.002.002.002.00NAMeanNA14200.2500.9210.9883.95525165652.4SDNA21400.250-1.00NANANANANANACV%NA151NANANANANANANAC0 initial concentration, Cmax peak serum concentration, Tmax time of Cmax, AUC(0-t) area under curve to last quantifiable timepoint, AUC(0-inf) area to infinity, T1/2 terminal half-life, Vz volume of distribution, CL clearance, F oral bioavailability, NA not applicable, NR not reported (AUC extrapolated >20%or r ² <0.8).aOral Cl and Vz calculated using apparent values (Cl/F, Vz/F). F% based on mean AUCinf (IV vs PO) due to non-crossover design.Table 2Pharmacokinetic parameters of CADD522 following IV (5 mg/kg) and PO (25 mg/kg) administration to 2 male Beagle dogsRouteDose Level (mg/kg)Animal numberC0 (nmol/L)Cmax (nmol/L)Tmax (h)AUC(0-t) (umol/L)AUC(0-inf) (umol/L)T1/2 (h)Vz (L/kg)CL (mL/min/kg)F (%)IV5021 MNR3050.2500.1860.1890.33839.51350NA024 M6114030.08300.1850.1880.35341.51360NAN1.002.002.002.002.002.002.002.00NAMeanNA3540.1670.1860.1880.34640.51350NAPO25021 MNA4610.2500.5790.5960.725135a2140a62.9024 MNA8320.2500.6750.6830.59295.9a1870a72.0NNA2.002.002.002.002.002.002.002.00MeanNA6460.2500.6270.6390.659115201067.5C0 initial concentration, Cmax peak serum concentration, Tmax time of Cmax, AUC(0-t) area under curve to last quantifiable timepoint, AUC(0-inf) area to infinity, T1/2 terminal half-life, Vz volume of distribution, CL clearance, F oral bioavailability, NA not applicable, NR not reported (AUC extrapolated >20%or r ² <0.8).aOral Cl and Vz calculated using apparent values (Cl/F, Vz/F). F% based on mean AUCinf (IV vs PO) due to non-crossover design. Pharmacokinetics and tolerability in CD-1 (n = 6) and Nude (n = 5) mice. a Schematic showing CADD522 tolerability schedules and animals. b Plasma levels following single 40 mg/kg IP, IV or PO dosing (CD-1 mice). c Blood cell profiles after 8 days of twice-daily 40 mg/kg PO dosing (nude mice). d Organ toxicity markers (ALT, AST, ALP, ALB, Prot, Calc, CreatK, Uric, Trig, Chol, Gluc). Significant differences shown (p-values). WBC white blood cells/leukocytes, RBC red blood cells, NUT neutrophils, Mono monocytes, Baso basophils, Luc large unstained cells, which correlate with markers of immune activation and helper T cell (CD4) counts, ALT alanine transaminase, AST aspartate transaminase, ALP alkaline phosphatase, ALB albumin, Prot total protein, Calc calcium, CreatK creatinine kinase, Uric uric acid; Trig, triglycerides; Chol, cholesterol, Gluco glucose. Standard units on the x-axis are specific for each enzyme/metabolite. Pharmacokinetics after single dose in rats (n = 6) and dogs (n = 2). a–f Plasma concentrations in Sprague Dawley rats (IV 5 mg/kg, PO 25 mg/kg). g–l Plasma concentrations in Beagle dogs (IV 5 mg/kg, PO 25 mg/kg). Linear and log plots shown for individual and mean values. m in vitro hepatic clearance of 10 µM [14C]-testosterone and n 1 µM CADD522 in mice, rats, dogs, minipigs and humans. Experiments were performed in duplicate. Table 1Pharmacokinetic parameters of CADD522 following IV (5 mg/kg) and PO (25 mg/kg) administration to 6 male Sprague Dawley ratsRouteDose level (mg/kg)Animal numberC0(nmol/L)Cmax(nmol/L)Tmax (h)AUC(0-t)(umol/L)AUC(0-inf) (umol/L)T1/2 (h)Vz(L/kg)CL(mL/min/kg)F (%)IV5001 M5514100.08300.261NRNRNRNRNA002 M5253680.08300.2190.2600.88074.7981NA003 M6024690.08300.4550.4911.1451.2519NAN3.003.003.002.002.002.002.002.00NAMean5594150.08300.3120.3761.0170.0750NASD39.450.7NA126NANANANANACV%7.0412.2NA40.5NANANANANAPO25004 MNA38900.2501.341.454.58350a882aNA005 MNA2221.000.5010.5263.32699a2430aNA006 MNA1350.250NRNRNRNRNRNANNA3.003.002.002.002.002.002.00NAMeanNA14200.2500.9210.9883.95525165652.4SDNA21400.250-1.00NANANANANANACV%NA151NANANANANANANAC0 initial concentration, Cmax peak serum concentration, Tmax time of Cmax, AUC(0-t) area under curve to last quantifiable timepoint, AUC(0-inf) area to infinity, T1/2 terminal half-life, Vz volume of distribution, CL clearance, F oral bioavailability, NA not applicable, NR not reported (AUC extrapolated >20%or r ² <0.8).aOral Cl and Vz calculated using apparent values (Cl/F, Vz/F). F% based on mean AUCinf (IV vs PO) due to non-crossover design. Pharmacokinetic parameters of CADD522 following IV (5 mg/kg) and PO (25 mg/kg) administration to 6 male Sprague Dawley rats C0 initial concentration, Cmax peak serum concentration, Tmax time of Cmax, AUC(0-t) area under curve to last quantifiable timepoint, AUC(0-inf) area to infinity, T1/2 terminal half-life, Vz volume of distribution, CL clearance, F oral bioavailability, NA not applicable, NR not reported (AUC extrapolated >20%or r ² <0.8). aOral Cl and Vz calculated using apparent values (Cl/F, Vz/F). F% based on mean AUCinf (IV vs PO) due to non-crossover design. Table 2Pharmacokinetic parameters of CADD522 following IV (5 mg/kg) and PO (25 mg/kg) administration to 2 male Beagle dogsRouteDose Level (mg/kg)Animal numberC0 (nmol/L)Cmax (nmol/L)Tmax (h)AUC(0-t) (umol/L)AUC(0-inf) (umol/L)T1/2 (h)Vz (L/kg)CL (mL/min/kg)F (%)IV5021 MNR3050.2500.1860.1890.33839.51350NA024 M6114030.08300.1850.1880.35341.51360NAN1.002.002.002.002.002.002.002.00NAMeanNA3540.1670.1860.1880.34640.51350NAPO25021 MNA4610.2500.5790.5960.725135a2140a62.9024 MNA8320.2500.6750.6830.59295.9a1870a72.0NNA2.002.002.002.002.002.002.002.00MeanNA6460.2500.6270.6390.659115201067.5C0 initial concentration, Cmax peak serum concentration, Tmax time of Cmax, AUC(0-t) area under curve to last quantifiable timepoint, AUC(0-inf) area to infinity, T1/2 terminal half-life, Vz volume of distribution, CL clearance, F oral bioavailability, NA not applicable, NR not reported (AUC extrapolated >20%or r ² <0.8).aOral Cl and Vz calculated using apparent values (Cl/F, Vz/F). F% based on mean AUCinf (IV vs PO) due to non-crossover design. Pharmacokinetic parameters of CADD522 following IV (5 mg/kg) and PO (25 mg/kg) administration to 2 male Beagle dogs C0 initial concentration, Cmax peak serum concentration, Tmax time of Cmax, AUC(0-t) area under curve to last quantifiable timepoint, AUC(0-inf) area to infinity, T1/2 terminal half-life, Vz volume of distribution, CL clearance, F oral bioavailability, NA not applicable, NR not reported (AUC extrapolated >20%or r ² <0.8). aOral Cl and Vz calculated using apparent values (Cl/F, Vz/F). F% based on mean AUCinf (IV vs PO) due to non-crossover design. In vitro metabolic stability of CADD522 was then evaluated in mouse, rat, dog, minipig and human hepatic microsomes. Cytochrome P450 (CYP450) monooxygenase processing using 10 μM [14C]-testosterone as the positive control (Fig. 4m) showed species differences in intrinsic clearance, with rapid metabolism observed in rodent microsomes and greater stability in higher species (Fig. 4n). In mouse microsomes, CADD522 was rapidly depleted with only half the parent compound remaining by 30 min (Fig. 4n). In contrast, degradation was slower in higher species’ microsomes (Fig. 4n), indicating moderate metabolic stability. Notably, CADD522 was most stable in human microsomes with a substantial fraction of parent compound remaining over the duration of the assay (Fig. 4n), suggesting comparatively low intrinsic clearance. CADD522 engages RUNX2 and structure-function analogues Cellular thermal shift assay (CETSA) confirmed dose-dependent RUNX2 engagement (EC50 116 nM) with CADD522 stabilising RUNX2 at 55 °C (Fig. 5a-d; Supplementary Fig. S1c, d). Structural analogue testing revealed that a bulky weak electron-withdrawing group at carbon-4 was essential for drug activity (Fig. 5e-h). Functional assays using an in vitro spheroid model showed that CADD522 and active analogues inhibited growth of RUNX2-expressing TWIST2+ cells but not RUNX2-negative PHMLEB cells (Fig. 6a-c).Fig. 5Cellular thermal shift assay (CETSA) and analogue activity.a–d RUNX2 CETSA: melting profile without drug (Tagg(75) = 52.5 °C) and dose-dependent CADD522 stabilisation (EC50 = 116 nM). e Lead analogues (>89% similarity) identified via hit2lead. f,–g CFA assays of CADD522 and analogues at varying doses. h Core structure and side group features relevant to activity.Fig. 6Structure-activity relationships and spheroid inhibition.a Spheroid area in PHMLEB and TWIST2+ cells treated with CADD522, CADD751 (active), or CADD513 (inactive). b Spheroid diameter under same conditions. c Representative 2X images after 1 week of treatment. Cellular thermal shift assay (CETSA) and analogue activity. a–d RUNX2 CETSA: melting profile without drug (Tagg(75) = 52.5 °C) and dose-dependent CADD522 stabilisation (EC50 = 116 nM). e Lead analogues (>89% similarity) identified via hit2lead. f,–g CFA assays of CADD522 and analogues at varying doses. h Core structure and side group features relevant to activity. Structure-activity relationships and spheroid inhibition. a Spheroid area in PHMLEB and TWIST2+ cells treated with CADD522, CADD751 (active), or CADD513 (inactive). b Spheroid diameter under same conditions. c Representative 2X images after 1 week of treatment. Discussion Osteoporosis remains a major cause of age-related disability despite the availability of effective antiresorptive and anabolic therapies. Although current treatments reduce fracture risk, long-term adherence is limited by adverse effects, contraindications and the need for repeated administration by a trained healthcare professional, highlighting the continued need for therapeutics with alternative mechanisms of action. In this study, we demonstrate that pharmacological inhibition of RUNX2 using the small molecule CADD52214–16 protects against ovariectomy-induced bone loss while simultaneously reducing adiposity and selectively remodelling systemic lipid metabolism. Together with evidence of direct target engagement, oral bioavailability and favourable early tolerability, these findings identify RUNX2 inhibition as a therapeutic strategy with potential applications extending beyond its original development as an anticancer agent. RUNX2 is widely recognised as the master regulator of osteoblast differentiation and skeletal development18,23–28, making the observation that pharmacological RUNX2 inhibition improves bone architecture initially counterintuitive. However, developmental functions of transcription factors frequently differ from their roles in mature tissues29–31. Our findings support the concept that RUNX2 contributes to pathological remodelling in the adult skeleton, where its inhibition enhances bone formation and preserves trabecular architecture following oestrogen deficiency. Rather than suppressing bone turnover globally, CADD522 increased circulating P1NP without altering βCTX, consistent with a net anabolic response. Histological changes in osteoclast distribution further suggest that RUNX2 inhibition modifies remodelling dynamics rather than simply inhibiting osteoclastogenesis. Together, these observations indicate that preservation of skeletal integrity is achieved through restoration of balanced bone remodelling rather than conventional antiresorptive activity. The concept of combining osteoanabolic and anti-remodelling activities within a single therapeutic platform has gained increasing attention in bone regenerative medicine. Hydroxyapatite-based multifunctional nanocomposites co-delivering bisphosphonates together with osteogenic ions, including zinc32 or strontium33, have previously demonstrated synergistic enhancement of bone regeneration while simultaneously suppressing pathological bone resorption. Similarly, zoledronate-loaded hydroxyapatite nanoparticles have improved bone remodelling through concurrent osteoconductive and antiresorptive effects34. These earlier studies illustrate the therapeutic value of integrating complementary biological activities within a single intervention rather than relying on agents that exclusively stimulate bone formation or inhibit resorption. Contrastingly to these biomaterial-based approaches, CADD522 achieves biological activity through pharmacological inhibition of the RUNX2 transcription factor, simultaneously preserving trabecular architecture, promoting bone formation and reducing adiposity and metabolic dysfunction. Although mechanistically distinct, these findings place CADD522 within the broader landscape of multifunctional bone therapeutics and support the concept that coordinated modulation of skeletal and metabolic pathways may provide greater therapeutic benefit than those targeting bone remodelling alone. A remarkable finding was that the skeletal improvements occurred alongside reduced peripheral and marrow adiposity and selective remodelling of lipid metabolism. Oestrogen deficiency is accompanied by profound metabolic changes that extend beyond bone, including increased adiposity and altered lipid handling. CADD522 consistently reduced body weight, inguinal fat mass and marrow adipocyte accumulation without evidence of UCP1-mediated thermogenesis, suggesting that these effects are unlikely to reflect increased energy expenditure through adipose browning. Lipidomic profiling in the lipid-rich brain further demonstrated preferential normalisation of long-chain saturated and monounsaturated fatty acids while largely preserving n-3 polyunsaturated fatty acids. Rather than inducing indiscriminate metabolic disruption, RUNX2 inhibition therefore appears to restore specific lipid pathways perturbed by menopause. These observations are notable because menopause is associated with widespread disruption of brain lipid homeostasis that has been linked to cognitive decline, and dietary n-3 polyunsaturated fatty acid supplementation has previously been shown to partially mitigate these changes35,36. Although the relationship between altered brain lipid composition and cognitive function was not examined in the present study, the selective remodelling of brain lipids following CADD522 treatment raises the possibility that RUNX2 inhibition may influence neurological adaptations to menopause in addition to preserving skeletal integrity. Future studies should determine whether these metabolic effects translate into improvements in cognition or other measures of brain health. More broadly, accumulating evidence implicates RUNX2 in transcriptional programmes regulating lipid metabolism across multiple tissues, supporting an emerging role for RUNX2 as a coordinator of skeletal and metabolic homeostasis. Translation of transcription factor inhibitors has historically been constrained by uncertainties regarding target engagement and drug-like properties. Here, cellular thermal shift assays confirmed direct engagement of RUNX2 at sub-micromolar concentrations, while structure-activity relationship studies demonstrated that closely related analogues exhibited substantially reduced biological activity, supporting the specificity of CADD522. Cross-species pharmacokinetic studies further demonstrated oral absorption and favourable short-term tolerability despite relatively rapid systemic clearance. Importantly, hepatic microsome studies showed greater metabolic stability in human than rodent microsomes, suggesting that preclinical rodent pharmacokinetics may underestimate persistence in humans. Nevertheless, rapid in vivo clearance remains the principal developability challenge and provides a clear rationale for medicinal chemistry optimisation or formulation strategies to extend systemic exposure while maintaining target engagement. Several limitations should be acknowledged. The efficacy studies were performed in a single ovariectomy model, and longer-term studies will be required to determine whether the skeletal benefits are maintained and ultimately reduce fracture risk. Lipidomic analyses were performed in a limited number of animals and therefore identify metabolic associations rather than establish causal mechanisms. Furthermore, although RUNX2 engagement was confirmed biophysically, the downstream transcriptional programmes responsible for the observed skeletal and metabolic phenotypes remain to be defined. Future studies should also investigate whether medicinal chemistry optimisation or advanced drug-delivery approaches, including sustained-release formulations or bone-targeted delivery systems, can enhance systemic exposure while preserving the favourable pharmacodynamic properties of CADD522. In summary, our findings reveal an unexpected role for RUNX2 inhibition in protecting against post-menopausal bone loss while simultaneously improving systemic metabolic homeostasis. By integrating efficacy, lipidomics, pharmacokinetics, toxicology and direct target engagement, this study establishes a translational framework for further development of CADD522 and identifies RUNX2 as a therapeutically tractable regulator of skeletal and metabolic adaptation in adulthood. Methods CADD522 preparation CADD522 (Chembridge, 5221975; PubChem CID: 2834870) was >90% pure (HPLC) and stored at −20 °C. For in vivo use, CADD522 was dissolved in sterile DMSO/PBS/HPβCD (10%/70%/20% v/v/v), sonicated and filtered (0.22 μM PVDF). In vivo efficacy studies The study design was approved by the Animal Welfare and Ethical Review Body of the University of East Anglia Research Ethics Committee and performed under Project Licence PP5500397. All procedures complied with UK Home Office guidelines and the Animals (Scientific Procedures) Act 1986. Five-week-old female C57BL/6 J mice were randomised and underwent OVX or sham surgery under 2% isoflurane anaesthesia. After two-week recovery with free access to sunflower seeds for 5 days, sham (n = 16) and OVX (n = 16) mice received either 25 mg/kg CADD522 (n = 8) or DMSO/PBS vehicle (n = 8) via IP injection three times per week for eight weeks. Clinical signs were monitored. At study endpoint, animals were humanely killed using Schedule 1-regulated procedures: respiratory and cardiac arrest by increasing CO2 concentration and cervical dislocation. Tibias were fixed in neutral buffered formalin then stored in 70% ethanol at 4 oC. Inguinal fat analysis Total body weight of the mice was measured three times per week. At study endpoint, the bilateral inguinal fat pads located adjacent to the genitals and running along the inner thighs were dissected by separation from the surrounding connective tissue using blunt dissection and fine forceps. Fat pads were weighed and stored en bloc at −80 oC. Bone markers At in vivo endpoint, 1 mL whole blood was collected into K2EDTA tubes (Greiner Bio-One, 454024). Blood samples were centrifuged at 751 × g at 4 °C for 10 min before plasma was separated and stored at −80 °C. Plasma P1NP (IDS, IS-4000) and βCTX (IDS, IS-3000N) were measured by ELISA with intra-assay CV < 6% and LoQ of 0.33 and 4.5 ng/mL, respectively. µ-CT Tibias were scanned using the SkyScan 1174 (8.3 μm voxel resolution, 50 kV, 800 μA, 0.5 mm Al filter). Trabecular region-of-interest commenced below the growth plate and extended 208 slices (1.72 mm). Thresholding (80 density units) distinguished mineralised from non-mineralised tissue. Suprascapula adipose tissue Cadavers were inspected post-mortem for suprascapula white adipose tissue. Fat pads were photographed with a FinePix S9400W (Fujifilm). Histology Bones were decalcified in 14% EDTA over 10 days, paraffin-embedded and sectioned (5 µm) onto glass slides. Slides were dewaxed, rehydrated and stained with either haematoxylin and eosin (H&E) or TRAP stain (TRAP solution and then counterstained with 0.2% methyl green), dehydrated and mounted in DPX. UCP1 assays Thermostability of purified ovine UCP1 was assessed by CPM dye-based fluorescence melt analysis37,38. Liposome reconstitution with SPQ probe was used to assess proton flux39–43. Fatty acid profiling Total lipids from whole brain samples (n = 3/group) were extracted as previously described44. Non-lipid impurities were removed by washing with 0.88% (w/v) potassium chloride. Lipid weight was determined gravimetrically after solvent evaporation and overnight desiccation under vacuum. Fatty acid methyl esters (FAMEs) were prepared by acid-catalysed transesterification of total lipids45. Extraction and purification of FAMEs was performed as previously described46 before being separated by gas-liquid chromatography using a Trace GC 2000 (Thermo Fisher Scientific) equipped with a fused silica capillary column (ZBWax, 60 m × 0.32 × 0.25 mm inner diameter; Danaher) with hydrogen as carrier gas and using on-column injection. Temperature gradient was 50–150 °C at 40 °C/min, then to 195 °C at 1.5 °C/min, and finally to 220 °C at 2 °C/min. Individual methyl esters were identified by comparison to known standards (Supelco 37-Fame Mix; MilliporeSigma) and by reference to previously published data44. Data were collected and processed using the Chromcard for Windows (v.2.00) computer package (Thermoquest). Fatty acid content per gram of tissue was calculated using heptadecanoic acid as internal standard. In vivo toxicology The study design was approved by the Institutional Animal Care and Use Committee at the University of Maryland. All procedures complied with The Animal Welfare Act. Female CD-1 (n = 6) and nude mice (n = 5) received a single IP, IV or PO 40 mg/kg dose or repeated PO dosing (40 mg/kg BID × 8 days). Plasma was collected at multiple timepoints and analysed by LC-MS/MS. At study endpoint, mice were humanely killed in accordance with the American Veterinary Medical Association Guidelines for the Euthanasia of Animals: respiratory and cardiac arrest by increasing CO2 concentration and cervical dislocation. In vivo PK The study design was approved by the Animal Welfare and Ethical Review Body of Charles River Laboratories, Edinburgh, UK and performed under Project Licence PP9376768. All procedures complied with UK Home Office guidelines and the Animals (Scientific Procedures) Act 1986. Male Sprague Dawley rats (n = 6) received 5 mg/kg IV or 25 mg/kg PO CADD522. Male Beagle dogs (n = 2) received 5 mg/kg IV, and one-week later, received 25 mg/kg PO. Plasma was collected up to 24 h and analysed by LC-MS/MS. At study endpoint, rats were humanely killed using Schedule 1 procedures: respiratory and cardiac arrest by increasing CO2 concentration and cervical dislocation. Dogs were adopted through a beagle rehoming scheme. Hepatic microsome metabolism assay 1 × 106 primary hepatocytes and hepatic microsomes from CD-1 mice, Sprague Dawley rats, Beagle dogs, Göttingen minipigs and humans (Discovery Life Sciences) were plated into 12-well plates and incubated in duplicates in a shaking water bath set to 37 oC with 1 µM CADD522 or 10 µM [14C]-testosterone (positive control), 1 mM nicotinamide adenine dinucleotide phosphate (NADPH) and incubation medium in a final volume of 1 mL. After 0, 5, 15, 30, 45, 60 and 120 min, 100 µL aliquots of the incubation supernatant were combined with an equal volume (100 µL) of ice-cold termination solvent. Experiments in heat-deactivated microsomes and blank samples (negative controls) were conducted in parallel. Terminated samples were transferred to a −20 oC freezer for 30 min then allowed to reach room temperature, vortex-mixed and particulate matter removed by centrifugation at 10,000 × g for 10 min. [14C]-testosterone was detected by stable isotope dilution (SID)-LC-MS/MS47. CADD522 was detected by LC-MS/MS. In vitro intrinsic clearance (CLint in units of mL/min/kg) was then calculated from in vitro t1/2 data using the following parameters: hepatocytes per gram liver (million cells/g; mouse=135, rat = 120, dog = 240, minipig = 124, human = 120) and liver weight per kg of body weight (g/kg; mouse = 87.5, rat = 40, dog = 32, minipig = 16, human = 25.7). LC-MS/MS CADD522 was quantified using LC-MS/MS (SCIEX API 4000, negative ESI) with tizoxanide (Merck, SML2837) as internal standard. The assay was linear (6–766 nmol/L; r²>0.98), with intra- and inter-assay CVs ≤15% and recovery of 74–104%. Cell culture PHMLEB (RRID: CVCL_DG84; human breast epithelium) stably expressing TWIST2 named TWIST2+ cells were kindly provided by Michele Vitolo and Stuart Martin at the University of Maryland Greenebaum Cancer Center. MCF7 (RRID: CVCL_0031; human ER+ breast cancer) were obtained from the American Type Culture Collection. Cells were authenticated by STR profiling48. PHMLEB and TWIST2+ cells were cultured in MEBM (Lonza, 11695430) supplemented with SingleQuots Supplement CC-4136 (Lonza, CC-3150). MCF7 were cultured in DMEM (Lonza, BE15-604K) supplemented with 10% FBS and 1% (v/v) penicillin/streptomycin. Cells were maintained at 37 °C in 5% CO2. Experiments were performed with Mycoplasma free cells. Adherent tissue culture plates were precoated with FNC Coating Mix (AthenaES, ACT1-0407-100). Ultra-low attachment plates (Corning, 3261) and EBM-2 (Lonza, CC-3162) were used for the suspension cultures. CETSA RUNX2 engagement in MDA-MB-231 cells (RRID: CVCL_0062; human triple-negative breast cancer) was tested using CETSA49,50 applying a 38–60 °C gradient with/without CADD522 (0.64-10,000 nM) for 10 min. After centrifugation at 14,000 × g to remove denatured protein, supernatant was collected and resolved via SDS-PAGE followed by immunoblot analysis with RUNX2 antibody (Cell Signaling Technologies, 8486S). Bands were quantified with a C-DiGit Blot Scanner (LI-COR Biosciences) and subsequent Tagg(50) and Tagg(75) values, described as temperatures at which 50/75% of the initial protein was reduced, respectively, were calculated. In vitro assays Clonogenic growth of MCF7 cells was assessed by CFA after CADD522 or analogue treatment (20, 100 μM) over 21 days. Colonies were fixed in 3:1 methanol-acetic acid solution, stained with 0.5% crystal violet and washed with PBS. Spheroid growth of PHMLEB and TWIST2+ cells (~100,000 cells/well) was measured after CADD522 (0, 10, 50 μM) over 14 days. Spheroids were photographed and measured from 4 fields per well and averaged from duplicate wells. Statistical analyses Data were analysed using Prism v7 (GraphPad), SPSS v28 (IBM) and Stata v14 (StataCorp). Data distributions were assessed for normality using the Shapiro-Wilk test prior to parametric analyses. Comparisons among three or more independent groups were performed using one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons test. Comparisons between two independent groups were performed using two-tailed unpaired t-tests, with Welch’s correction applied where variances were unequal. Paired t-tests were used for matched observations. Results are presented as mean ± SEM or SD, as indicated. A two-sided p < 0.05 was considered statistically significant (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.005, ****p ≤ 0.001). Supplementary information Supplementary Fig. S1 Supplementary Data 1 Supplementary Fig. S1 Supplementary Data 1